We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > jPsA

News List

Cosentyx®displays a 72 percent reduced arthritis flare risk EuropeanPharmaceuticalReview
November 11, 2021
Novartis has announced new analyses from the two-year positive Phase III JUNIPERA study, which demonstrated the treatment response of Cosentyx® (secukinumab)...
Novartis Presents Positive Results from JUNIPERA Study Supporting Cosentyx as a Treatment in a JIA Population americanpharmaceuticalreview
June 04, 2021
Novartis, a leader in rheumatology and immuno-dermatology, announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx® (secukinumab) significantly delayed time to flare vs placebo (P<.001) in pediatric patients ...
Janssen Submits sBLA for SIMPONI ARIA for Juvenile Arthritis americanpharmaceuticalreview
April 26, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of two supplemental Biologics License Applications (sBLA).